# ROTH Capital Partners

> ROTH Capital Partners is a VC fund backing Health Care and Biotechnology. See 47 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Newport Beach, United States
- Total investments: 47
- Last investment: Jul 2026
- Lead investor: 43%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/roth-capital-partners/about/
- X (Twitter): https://twitter.com/rothcapital
- Website: http://www.roth.com
- Facebook: https://www.facebook.com/RothCapitalPartners/

ROTH Capital Partners is an investment banking firm dedicated to the small-cap public market.

## Contacts

5 contacts available for ROTH Capital Partners. Shizune tracks 7 team members at ROTH Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/roth-capital-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 11 | 23% |
| Biotechnology | 10 | 21% |
| Energy | 6 | 13% |
| Medical | 5 | 11% |
| Manufacturing | 5 | 11% |

86 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Post-IPO Equity | 24 | 51% |
| Series A | 4 | 9% |
| Funding Round | 4 | 9% |
| Series C | 3 | 6% |
| Private Equity | 3 | 6% |

11 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 31 | 66% |
| Israel | 4 | 9% |
| Canada | 3 | 6% |
| Australia | 1 | 2% |
| Puerto Rico | 1 | 2% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Byron Roth | Chairman & CEO | 1 | https://shizune.co/investors/profile/byron-roth |
| David Dohrmann | Managing Director | 0 | https://shizune.co/investors/profile/dave-dohrmann |
| Eric Cheng | Managing Director, Head of Healthcare Investment Banking | 0 | https://shizune.co/investors/profile/eric-cheng-3 |
| Hershel Gerson | MD, Co-Head of Consumer Investment Banking | 0 | https://shizune.co/investors/profile/hershel-gerson |
| James Antonopoulos | Managing Director, Head of Healthcare Investment Banking | 0 | https://shizune.co/investors/profile/james-antonopoulos |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Polar Power | Polar Power designs, manufactures, and distributes direct current power generation systems and related technologies. The company develops DC-based power systems, DC hybrid power systems, and DC solar hybrid power systems in fuel formats such as diesel, natural gas, propane, and renewable alternatives. Its products are used in sectors includingtelecommunications, defense, renewable energy, marine, automotive, and industrial operations. In addition to power generation equipment, it offers technologies for battery charging and combined heat and power (CHP) systems. | $25M | Post-IPO Equity | Jul 27, 2026 |  |
| Peraso Technologies | Peraso Technologies Inc., a fabless semiconductor company, specializes in the development of multi-gigabit millimeter wave single-chip transceivers for the mobile consumer electronics market. The company also provides custom solutions tailored to customer-specific opportunities. Its products are used for mobile rapid sync-n-go, desktopinterconnect, wireless networking, in-room HD video streaming, cellular backhaul, wireless links, medical and security imaging, vehicle-to-vehicle communication, and IC-to-IC links applications.Peraso Technologies Inc. is based in Toronto, Canada. | $17.6M | Post-IPO Equity | Jul 02, 2026 |  |
| Odysight.AI | Odysight.AI is an AI platform that specializes in visualizing, analyzing, predictive maintenance, and monitoring solutions. | $20M | Post-IPO Equity | Jun 05, 2026 |  |
| RoboStrategy | RoboStrategy is a venture capital investment firm that publicly trades a fund giving investors access to private & public companies leading in robotics and embodied AI. | $2B | Post-IPO Equity | May 15, 2026 |  |
| Stereotaxis | Stereotaxis focuses on the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. With over 100 patents for use in a hospital's interventional surgical suite, Stereotaxis helps physiciansaround the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced collaboration of life-saving information. Stereotaxis' core technologies are the Niobe® ES Remote Magnetic Navigation system, the Odyssey™ portfolio of lab optimization, networking and patient information management systems and the Vdrive™ Robotic Mechanical Navigation system and consumables. | $50M | Post-IPO Equity | Aug 29, 2025 |  |
| Moleculin | Moleculin Biotech is a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Their clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studiedfor the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer, and AML. They are also engaged in the preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors. | $3.5M | Post-IPO Equity | Feb 25, 2025 |  |
| Moleculin | Moleculin Biotech is a clinical-stage pharmaceutical company focused on the development of oncology drug candidates, some of which are based on discoveries made at M.D. Anderson Cancer Center. Their clinical stage drugs are Annamycin, an anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity being studiedfor the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as AML, and WP1066, an immuno-stimulating STAT3 inhibitor targeting brain tumors, pancreatic cancer, and AML. They are also engaged in the preclinical development of additional drug candidates, including additional STAT3 inhibitors and compounds targeting the metabolism of tumors. | $5.8M | Post-IPO Equity | Feb 13, 2025 |  |
| Kept | Compassionate off-boarding services for departing employees. It's a lot more than just COBRA. | $2.1M | Seed | Jun 15, 2023 |  |
| New Found Gold Corp. | New Found Gold Corp. is actively exploring district size gold exploration projects in Newfoundland and Ontario. | $50M | Post-IPO Equity | Dec 07, 2022 |  |
| UNION | UNION develops a hospitality engagement platform that creates innovative experiences for guests, operators, and businesses. Its platform helps clients to materially boost their business sales, avoid staffing shortages, and attract more customers. | $22M | Series B | Dec 09, 2021 |  |

10 of 47 investments shown.

## Co-investors
- [Oak Investment Partners](https://shizune.co/investors/profile/oak-investment-partners) — VC Fund, 3 deals together
- [Shasta Ventures](https://shizune.co/investors/profile/shasta-ventures) — VC Fund, 3 deals together
- [Baseline Ventures](https://shizune.co/investors/profile/baseline-ventures) — VC Fund, 2 deals together
- [Cherry Tree Investments](https://shizune.co/investors/profile/cherry-tree-investments-2) — VC Fund, 2 deals together
- [Clinton Capital Partners](https://shizune.co/investors/profile/clinton-capital-partners) — VC Fund, 2 deals together
- [Granite Ventures](https://shizune.co/investors/profile/granite-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund
- [KB Securities](https://shizune.co/investors/profile/kb-securities) — VC Fund
- [Frazier Healthcare Partners](https://shizune.co/investors/profile/frazier-healthcare-ventures) — VC Fund

## FAQ

### What does ROTH Capital Partners invest in?

ROTH Capital Partners invests primarily in Health Care, Biotechnology and Energy startups, most often at Post-IPO Equity and Series A stage. Most of the 47 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact ROTH Capital Partners?

Public channels for ROTH Capital Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at ROTH Capital Partners?

The team at ROTH Capital Partners includes Byron Roth (Chairman & CEO), David Dohrmann (Managing Director) and Eric Cheng (Managing Director, Head of Healthcare Investment Banking), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co